IP Library Granted Patent US 8,227,410
Granted Patent B2
US 8,227,410 · App. 13/049,308 · Granted Jul 24, 2012

Methods of stimulating wound healing by administration of vascular endothelial growth factor D (VEGF-D)

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,227,410
App. No.
13/049,308
Granted
Jul 24, 2012
Kind
B2
Abstract

VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.

Claims (15)

1. A method of stimulating wound healing in a mammalian subject in need thereof, the method comprising administering to the subject a polypeptide that stimulates endothelial cell proliferation, wherein the polypeptide is

(a) a polypeptide comprising a fragment of the amino acid sequence of SEQ ID NO: 5, wherein said fragment and said polypeptide lack amino acids of SEQ ID NO: 5 that are N-terminal to residue 92 of SEQ ID NO: 5 and lack amino acids that are C-terminal to residue 205 of SEQ ID NO: 5;

(b) the polypeptide of (a) that comprises at least amino acids 101-196 of SEQ ID NO: 5; or

(c) a polypeptide that lacks amino acids of SEQ ID NO: 5 that are N-terminal to residue 93 of SEQ ID NO: 5 and lack amino acids that are C-terminal to residue 201 of SEQ ID NO: 5.

2. The method of claim 1 , wherein the polypeptide comprises amino acids 92-205 of SEQ ID NO: 5.

3. The method of claim 1 , wherein the polypeptide comprises amino acids 101-196 of SEQ ID NO: 5.

4. The method of claim 3 , wherein the polypeptide is administered by topical application.

5. The method of claim 3 , wherein the polypeptide is administered by subcutaneous injection.

6. The method of claim 3 , wherein the polypeptide is administered in an amount effective to accelerate angiogenesis in wound healing.

7. The method of claim 1 , wherein the polypeptide comprises amino acids 93-201 of SEQ ID NO: 5.

8. The method of claim 1 , wherein the polypeptide comprises amino acids 101-196 of SEQ ID NO: 5 and lacks amino acids of SEQ ID NO: 5 that are N-terminal to residue 92 of SEQ ID NO: 5 and lack amino acids that are C-terminal to residue 205 of SEQ ID NO: 5.

9. The method of claim 1 , wherein the polypeptide consists of amino acids 93-201 of SEQ ID NO: 5.

10. The method of claim 1 , wherein the polypeptide is administered by topical application.

11. The method of claim 1 , wherein the polypeptide is administered by subcutaneous injection.

12. The method of claim 1 , wherein the polypeptide is administered in an amount effective to accelerate angiogenesis in wound healing.

Assignments (1)
CHANGE OF NAME Recorded Jan 3, 2013
From: VEGENICS LIMITED
To: VEGENICS PTY LTD
Reel/Frame 029565/0926 →